A number of research firms have changed their ratings and price targets for ImmuPharma PLC (LON: IMM):

  • 10/4/2017 – ImmuPharma PLC had its “buy” rating reaffirmed by analysts at Northland Securities. They now have a GBX 181 ($2.40) price target on the stock.
  • 9/27/2017 – ImmuPharma PLC had its “buy” rating reaffirmed by analysts at Northland Securities. They now have a GBX 181 ($2.40) price target on the stock.
  • 9/21/2017 – ImmuPharma PLC had its “buy” rating reaffirmed by analysts at Northland Capital Partners. They now have a GBX 181 ($2.40) price target on the stock.
  • 9/21/2017 – ImmuPharma PLC had its “buy” rating reaffirmed by analysts at Northland Securities. They now have a GBX 181 ($2.40) price target on the stock.

ImmuPharma PLC (LON IMM) opened at 80.00 on Friday. The company’s market capitalization is GBX 103.61 million. The stock has a 50 day moving average of GBX 53.11 and a 200 day moving average of GBX 53.17. ImmuPharma PLC has a 12 month low of GBX 31.44 and a 12 month high of GBX 87.00.

ImmuPharma plc is a drug discovery and development company. The Company is focused on the development of drugs, primarily based on peptide therapeutics, to treat serious medical conditions such as autoimmune diseases. The Company has approximately five drug candidates in development, over two platform technologies and approximately 70 patents.

Receive News & Ratings for ImmuPharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.